Market Scenario
The nasal route administration is experiencing tremendous growth due to its noninvasive nature consequently reducing pain and threat of infections. It allows the patient to self-administer drugs thus not requiring any external help. The high vasculature, high permeability, and low enzymatic environment of nasal cavity are perfectly apt for systemic delivery of drug molecules via nose. There is no risk of drug destruction by hydrogen chloride (HCl) present in the stomach thereby increasing bioavailability which reduces the dosage of the drug. This, in turn, leads to proportional reduction in side effects.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2696
Increasing popularity of over-the-counter nasal drugs such as inhalers for the common cold is also propel the market in an upward manner. Nasal drugs prove to be advantageous for the market, with a plethora of factors like good penetration of the drugs into the nasal cavity, improving patient compliance, rapid absorption, onset of action, and requirement of low dosage.
Key Players
- Novartis AG
- Pfizer, Inc.
- Sanofi-Aventis
- Merck & Co., Inc.
- AptarGroup Inc.
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline plc
- Becton Dickson & Company
Drivers and Restraints
The market for nasal drug delivery is growing remarkably with a consistently good CAGR due to the benefits accompanying nasal drugs. Other driving factors include innovation of drugs which are absorbed easily from the nasal route, innovations in advanced products which allow the delivery of precise doses and also ease of administration. However, the restraints that threaten the growth of the market are irritation of the nasal route and the low dose of the drug that can be delivered as compared to other routes of administration. Other constraints include concurrent low popularity of the route which reduces economies of scale in producing these delivery devices and low awareness. According to an extensive report by Market Research Future (MRFR), the Middle East and Africa nasal drug delivery market is presumed to reach around USD 1.59 billion in 2022 surging at a CAGR of 8.1% from 2017 to 2022. The market was estimated to be worth USD 1 billion in 2015.
Regional Analysis
UAE is the largest market for nasal drug delivery in entire Middle East and Africa nasal drug delivery Market closely followed by Egypt. The rest of Africa’s market is growing at a very fast rate due to huge unmet medical needs and growing popularity of nasal route.
Segmentation
Middle East and Africa nasal drug delivery market has been segmented on the basis of dosage form which comprises of drops, sprays, powder, gels and ointments. On the basis of system, market is segmented into unit dose, multi-dose and metered dose. On the basis of delivery technologies; market is segmented into spray, nebulizers and other. On the basis of therapeutic applications; market is segmented into rhinitis, congestion, vaccinations and others.
Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696
No comments:
Post a Comment